 |
|
|
MRNA Description — Moderna Inc
Moderna, Inc. is a biotechnology company. Co. is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development.
| Company Name: |
Moderna Inc |
| Website: |
www.modernatx.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding MRNA: |
197 |
| Total Market Value Held by ETFs: |
$2,167,818,324.8 |
| Total Market Capitalization: |
$13,380,000,000 |
| % of Market Cap. Held by ETFs: |
16.20% |
|
| ETF |
MRNA Weight |
MRNA Amount |
| VTI |
0.02% |
$376,710,296 |
| VOO |
0.02% |
$315,334,945 |
| VO |
0.13% |
$255,953,609 |
| SPY |
0.02% |
$146,362,487 |
| VUG |
0.05% |
$141,111,947 |
| IVV |
0.02% |
$137,933,858 |
| RSP |
0.17% |
$121,687,767 |
| XBI |
1.99% |
$120,959,694 |
| XLV |
0.23% |
$86,362,871 |
| VOT |
0.28% |
$85,199,438 |
| List of all 197 ETFs holding MRNA
» |
|
|
|
|
|
Hold (2.12 out of 4)
0th percentile
|
PARTNER NEWS:Fri, Jan 17, 1:12 AM, Zacks
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
Moderna, Regeneron, Intellia Sage and GSK are included in this Analyst Blog.
Thu, Jan 16, 2:00 PM, Zacks
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?
We believe investors with a long-term horizon should hold MRK stock, while short-term investors should consider selling it.
|
|
Free MRNA Email Alerts:
